Solstein Capital’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
Solstein Capital's GILD Position: Q3 2026 in Review
Solstein Capital sold out of Gilead Sciences (GILD) in Q3 2026, closing a stake of 1,036 shares — an estimated $131K sold.
Solstein Capital first reported a position in GILD in Q4 2019 and held it in 26 quarters. The position peaked at $144K in Q1 2026. 2,328 funds tracked by Wall St. Rank hold GILD as of Q3 2026.
- Solstein Capital reported no remaining Gilead Sciences position as of Q3 2026 after selling out during the quarter.
- Solstein Capital sold 1,036 Gilead Sciences shares in Q3 2026, an estimated $131K.
- Solstein Capital first reported a position in Gilead Sciences in Q4 2019 and held it in 26 quarters.
- Solstein Capital's Gilead Sciences position peaked at $144K in Q1 2026.
- 2,328 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2026.
Based on Solstein Capital's 13F filing for Q3 2026, filed 2 Nov 2026.